IFNA1 and COVID-19: For example, in the plasmapheresis trials, multiple rounds of plasmapheresis were required to reduce anti-IFNα autoAb levels in four patients with severe COVID-19 (de Prost et al., 2021), yet this intervention failed to demonstrate improved clinical outcomes.